5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D1 receptor agonists in the 6-hydroxydopamine-lesioned rat

European Journal of Pharmacology

Volumn 398, Issue 1, 2000, Pages 59-64

  Fox, Susan H ^a   Brotchie, Jonathan M ^a  

^a G38 Stopford Building   (United Kingdom)

Author keywords

5 HT(2C) receptor; 6 Hydroxydopamine lesioned rat; Parkinson's disease; SKF 82958

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; LEVODOPA; OXIDOPAMINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZAZEPINES; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; INDOLES; LEVODOPA; LOCOMOTION; MALE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D1; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0034625597     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00238-7     Document Type: Article

References (41)

1. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
2. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Prog. Brain Res. 85:1990;119-146.
3. Arnt J., Bogeso K.P., Hyttel H., Meirer E. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol. Toxicol. 62:1988;121-130.
4. Barone P., Morelli M., Popoli M., Cicarelli G., Campanella G., Di C.G. Behavioural sensitization in 6-hydroxydopamine-lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation. Neuroscience. 61:1994;867-873.
5. Blanchet P., Bedard P.J., Britton D.R., Kebabian J.W. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol. Exp. Ther. 267:1993;275-279.
6. Brefel C., Soubrouillard C., Lafnitzegger K., Fabre N., Viallet F., Frederick E., Thalamas C., Azulay J.P., Senard A., Montastruc J.L., Wright S., Blin O., Nutt J., Rascol O. A D1 dopamine agonist, ABT-431 in patients with Parkinson's disease. Mov. Disord. 12:1997;233P. (Suppl.).
7. Brotchie J.M. Novel approached to the symptomatic treatment of Parkinsonian syndromes and adjuncts to dopamine-replacement. Curr. Opin. Neurol. 10:1997;340-345.
8. Brotchie J.M., Mitchell I.J., Sambrook M.A., Crossman A.R. Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus I rat and primate. Mov. Disord. 6:1991;133-138.
9. Duty S., Brotchie J.M. Enhancement of the behavioural response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
10. Fenu S., Carta A., Morelli M. Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra. Synapse. 19:1995;233-240.
11. Forbes I.T., Ham P., Booth D.H., Martin R.T., Thompson M., Baxter G.S., Blackburn T.P., Glen A., Kennett G.A., Wood M.D. 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity. J. Med. Chem. 38:1995;2524-2530.
12. Fox S.H., Brotchie J.M. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 301:1996a;27-30.
13. Fox S.H., Brotchie J.M. 5-HT2C receptor binding in Parkinson's disease. J Neurol. Neurosurg. Psychiatry. 61:1996b;537.
14. Fox S.H., Moser B., Brotchie J.M. Behavioural effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;35-49.
15. Hely M.A., Morris J.G., Reid W.G., O'Sullivan D.J., Williamson P.M., Rail D., Broe G.A., Margrie S. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J. Neurol. Neurosurg. Psychiatry. 57:1994;903-910.
16. Henry B., Crossman A.R., Brotchie J.M. Characterisation of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342.
17. Huang K., Walters J.T. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output. J. Pharmacol Exp. Ther. 271:1994;1434-1443.
18. Kennett G.A., Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br. J. Pharmacol. 94:1988;137-147.
19. Kennett G.A., Wood M.D., Glen A., Grewal S., Forbes I., Gadre A., Blackburn T.P. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br. J. Pharmacol. 111:1994;797-802.
20. Kennett G.A., Wood M.D., Bright F., Cilia J., Piper D.C., Gager T., Thomas D., Baxter G.S., Forbes I.T., Ham P., Blackburn T.P. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 117:1996;427-434.
21. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
22. Klockgether T., Turski L. NMDA antagonists potentiate anti-parkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
23. Loschmann P.A., Lange K.W., Kunow M., Rettig K.J., Jahnig P., Honore T., Turski L., Wachtel H., Jenner P., Marsden C.D. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J. Neural Transm. Parkinson's Dis. Dementia Sect. 3:1991;203-213.
24. Mengod G., Pompeiano M., Martinez M.M., Palacios J.M. Localisation of the mRNA for the 5-HT2 receptor by in situ hybridisation histochemistry. Correlation with the distribution of receptor sites. Brain. Res. 524:1990;139-143.
25. Morelli M., DiChiara G. Agonist-induced homologous and heterologous sensitization to D-1-and D-2-dependent contraversive turning. Eur. J. Pharmacol. 141:1987;101-107.
26. Morelli M., DiChiara G. MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J. Pharmacol. 182:1990;611-612.
27. Morelli M., Fenu S., Garau L., DiChiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 162:1989;329-335.
28. Morelli M., De M.G., DiChiara G. Changes in the D1 receptor-adenylate cyclase complex after priming. Eur. J. Pharmacol. 180:1990;365-367.
29. Nutt J.G. Levodopa-induced dyskinesias. Neurology. 40:1990;340-345.
30. O'Boyle K.M., Gaitanopoulos D.E., Brenner M., Waddington J.L. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology. 28:1989;401-405.
31. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated Parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
32. Paxinos G., Watson C. The Rat Brain Stereotaxic Atlas. 1996;Academic Press, Sydney.
33. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain: III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience. 21:1987;97-122.
34. 3H]SCH 23390 labelled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur. J. Pharmacol. 114:1985;235-237.
35. Rascol O., Brooks D.J., Brunt E.R., Korczyn A.D., Poewe W.H., Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5 year Levodopa-controlled study. Mov. Disord. 13:1998;39-45. on behalf of the 056 Study Group.
36. Rick C.E., Stanford I.M., Lacey M.G. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience. 69:1995;903-913.
37. Thomas J., Wang J., Takubo H., Sheng J., De Jesus S., Bankiewicz K.S. A 6-hydroxydopamine-induced selective Parkinsonian rat model: further biochemical and behavioural characterisation. Exp. Neurol. 126:1994;159-167.
38. Trugman J.M., Wooten G.F. Selective D1 and D2 dopamine agonist differentially alter basal ganglia glucose utilisation in rats with unilateral 6-hydroxydopamine substantia nigra lesions. J. Neurosci. 7:1987;2927-2935.
39. Walters J.R., Bergstrom D.A., Carlson J.H., Chase T.N., Braun A.R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 236:1987;719-722.
40. Watts R.L. The role of dopamine agonists in early Parkinson's disease. Neurology. 49:1997;35-49. (Suppl.).
41. Weick B.G., Engber T.M., Suzel Z., Chase T.N., Walters J.R. Responses of substantia nigra pars reticulata neurons to GABA and SKF38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Res. 523:1990;16-22.